SavaDx

About Cassava Sciences

Cassava Sciences is dedicated to advancing innovative therapies for neurodegenerative diseases, with a primary focus on Alzheimer's. Its core technology centers on targeting altered filamin A (FLNA) protein, which the company believes is a key pathological driver of the disease. The company's lead candidate, simufilam, has progressed through Phase 2 and Phase 3 clinical trials, generating significant data and investor attention, though not without controversy. Cassava's strategy is to develop an oral, disease-modifying treatment that could potentially slow or halt the progression of Alzheimer's.

Therapeutic Areas